Welcome to our dedicated page for Maze Therapeutics news (Ticker: MAZE), a resource for investors and traders seeking the latest updates and insights on Maze Therapeutics stock.
Maze Therapeutics, Inc. (Nasdaq: MAZE) is a clinical-stage biopharmaceutical company that regularly reports news on the progress of its genetics-guided kidney and metabolic disease programs. Company updates often highlight developments in its lead oral small molecule candidates, MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, as well as broader corporate and financial milestones.
News items from Maze commonly cover clinical trial milestones, such as Phase 1 and Phase 2 study results, enrollment updates, and plans for upcoming proof-of-concept trials. For example, the company has issued press releases on first-in-human data for MZE782 in healthy volunteers, describing safety, pharmacokinetics, and pharmacodynamic markers like urinary amino acid excretion and changes in estimated glomerular filtration rate. It has also provided regular updates on the Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease.
Investors and followers of MAZE can also expect financial results announcements, including quarterly earnings press releases furnished on Form 8-K, which summarize research and development spending, cash position, and license revenue. In addition, Maze issues news about financing transactions, such as its oversubscribed private placement of common stock and pre-funded warrants, along with related registration statements for resale of those securities.
Maze’s news flow also includes corporate governance and leadership updates, such as the appointment of a new chief financial officer and the selection of a new chairman of the board, as well as participation in healthcare and investor conferences where management presents the company’s strategy and pipeline. Conference-related releases typically provide webcast details for investors.
This news page aggregates these disclosures so readers can follow Maze’s clinical progress, financing activities, and corporate developments in one place. For investors and observers tracking MAZE, the feed offers a structured view into how the company’s genetics-based approach and lead programs are evolving over time.
Maze Therapeutics (MAZE) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical programs. The company successfully completed an upsized IPO in February 2025, raising $140 million in gross proceeds at $16.00 per share, following a $115 million Series D financing in November 2024.
Key pipeline developments include the Phase 2 HORIZON trial of MZE829 for APOL1 Kidney Disease (AKD), with initial data expected in Q1 2026, and ongoing Phase 1 trials of MZE782 for chronic kidney disease (CKD) and phenylketonuria (PKU), with data expected in H2 2025.
Financial highlights for 2024 include license revenue of $167.5 million, primarily from a Shionogi agreement, and a net income of $52.2 million. Cash position stood at $196.8 million as of December 31, 2024, with runway expected into H2 2027.
Maze Therapeutics (NASDAQ: MAZE) has initiated patient dosing in its Phase 2 HORIZON clinical trial, evaluating MZE829, an oral APOL1 inhibitor for APOL1 kidney disease (AKD). The trial targets a condition affecting over one million patients in the United States.
The HORIZON Study employs an open-label basket design, enrolling AKD patients with two high-risk APOL1 alleles (G1, G2), stratified by clinical phenotype and proteinuria levels. The study includes patients with severe disease, nephrotic range proteinuria, FSGS, hypertensive nephropathy, and diabetic kidney disease, marking the first trial of a small molecule APOL1 inhibitor in diabetic AKD patients.
The primary endpoint focuses on reducing proteinuria, measured by a 30% or greater reduction in urinary albumin-to-creatinine ratio (uACR) at week 12. Maze anticipates an interim data readout in Q1 2026.
Maze Therapeutics (Nasdaq: MAZE), a clinical-stage biopharmaceutical company focused on developing precision medicines for renal, cardiovascular and metabolic diseases, has announced the pricing of its upsized initial public offering. The company is offering 8,750,000 shares of common stock at $16.00 per share, expecting to raise gross proceeds of $140.0 million.
The shares will begin trading on the Nasdaq Global Market on January 31, 2025, under the symbol 'MAZE'. The company has granted underwriters a 30-day option to purchase up to an additional 1,312,500 shares. The offering is expected to close on February 3, 2025. J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities are serving as joint bookrunning managers for the IPO.